Chart Of The Day: Fundamentals And Technicals Agree, Pfizer Is Heading Higher

 | Apr 13, 2021 23:24

The Director General of the World Health Organization, Tedros Adhanom Ghebreyesus, warned on Monday that the pandemic is “a long way from over,” due to confusion and complacency. According to WHO's assessment , the trajectory of COVID-19 is now “growing exponentially, with over 4.4 million new virus cases last week. Naturally, that only increases global demand for the vaccine.

Among the companies whose innocultions are already available and in use, including Moderna (NASDAQ:MRNA), AstraZeneca (NASDAQ:AZN) and Johnson & Johnson (NYSE:JNJ), Pfizer's vaccine appears to be the clear leader in the race to increase market share.

That's because recent clinical trials demonstrated the Pfizer (NYSE:PFE) shot is safe and effective for the 12-15 year old cohort as well as for those 16 and older who are currently receiving it. Which positions Pfizer’s vaccine to receive FDA emergency use authorization for younger adolescents, months ahead of the competition—before schools open in the fall.

The technical perspective for Pfizer stock also broadcasts its leadership, after PFE completed back-to-back bullish patterns.